retatrutide clinical trial weight loss results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a First Retatrutide phase 3 data,

This fragmented approach limits the sustainability of therapeutic effects, particularly in hypothyroid patients with profound metabolic and inflammatory dysregulation

CrossRef Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Kaleab Alemayehu Zewdie, Brhane Teklebrhan Assefa, Muluken Altaye Ayza Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020

Additionally, incretin-based therapies as a class carry a rare signal for pancreatitis , and rapid weight loss is associated with an increased risk of gallbladder disease (including gallstones)

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinsons disease

Ann Fam Med